Inhibition of the NEMO/IKKβ association complex formation, a novel mechanism associated with the NF-κB activation suppression by Withania somnifera’s key metabolite withaferin A by Grover, Abhinav et al.
PROCEEDINGS Open Access
Inhibition of the NEMO/IKKb association complex
formation, a novel mechanism associated with
the NF-B activation suppression by Withania




1, Virendra S Bisaria
1, Durai Sundar
1*
From Asia Pacific Bioinformatics Network (APBioNet) Ninth International Conference on Bioinformatics
(InCoB2010)
Tokyo, Japan. 26-28 September 2010
Abstract
Background: Nuclear Factor kappa B (NF-B) is a transcription factor involved in the regulation of cell signaling
responses and is a key regulator of cellular processes involved in the immune response, differentiation, cell
proliferation, and apoptosis. The constitutive activation of NF-B contributes to multiple cellular outcomes and
pathophysiological conditions such as rheumatoid arthritis, asthma, inflammatory bowel disease, AIDS and cancer.
Thus there lies a huge therapeutic potential beneath inhibition of NF-B signalling pathway for reducing these
chronic ailments. Withania somnifera, a reputed herb in ayurvedic medicine, comprises a large number of steroidal
lactones known as withanolides which show plethora of pharmacological activities like anti- inflammatory,
antitumor, antibacterial, antioxidant, anticonvulsive, and immunosuppressive. Though a few studies have been
reported depicting the effect of WA (withaferin A) on suppression of NF-B activation, the mechanism behind this
is still eluding the researchers. The study conducted here is an attempt to explore NF-B signalling pathway
modulating capability of Withania somnifera’s major constituent WA and to elucidate its possible mode of action
using molecular docking and molecular dynamics simulations studies.
Results: Formation of active IKK (IB kinase) complex comprising NEMO (NF-B Essential Modulator) and IKKb
subunits is one of the essential steps for NF-B signalling pathway, non-assembly of which can lead to prevention
of the above mentioned vulnerable disorders. As observed from our semi-flexible docking analysis, WA forms
strong intermolecular interactions with the NEMO chains thus building steric as well as thermodynamic barriers to
the incoming IKKb subunits, which in turn pave way to naive complex formation capability of NEMO with IKKb.
Docking of WA into active NEMO/IKKb complex using flexible docking in which key residues of the complex were
kept flexible also suggest the disruption of the active complex. Thus the molecular docking analysis of WA into
NEMO and active NEMO/IKKb complex conducted in this study provides significant evidence in support of the
proposed mechanism of NF-B activation suppression by inhibition or disruption of active NEMO/IKKb complex
formation being accounted by non-assembly of the catalytically active NEMO/IKKb complex. Results from the
molecular dynamics simulations in water show that the trajectories of the native protein and the protein
complexed with WA are stable over a considerably long time period of 2.6 ns.
Conclusions: NF-B is one of the most attractive topics in current biological, biochemical, and pharmacological
research, and in the recent years the number of studies focusing on its inhibition/regulation has increased
* Correspondence: sundar@dbeb.iitd.ac.in
1Department of Biochemical Engineering and Biotechnology, Indian Institute
of Technology (IIT) Delhi, Hauz Khas, New Delhi 110016, India
Full list of author information is available at the end of the article
Grover et al. BMC Genomics 2010, 11(Suppl 4):S25
http://www.biomedcentral.com/1471-2164/11/S4/S25
© 2010 Grover et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.manifolds. Small ligands (both natural and synthetic) are gaining particular attention in this context. Our
computational analysis provided a rationalization of the ability of naturally occurring withaferin A to alter the NF-B
signalling pathway along with its proposed mode of inhibition of the pathway. The absence of active IKK
multisubunit complex would prevent degradation of IB proteins, as the IB proteins would not get
phosphorylated by IKK. This would ultimately lead to non-release of NF-B and its further translocation to the
nucleus thus arresting its nefarious acts. Conclusively our results strongly suggest that withaferin A is a potent
anticancer agent as ascertained by its potent NF-B modulating capability. Moreover the present MD simulations
made clear the dynamic structural stability of NEMO/IKKb in complex with the drug WA, together with the
inhibitory mechanism.
Background
NF-B (Nuclear Factor kappa B) is a ubiquitous tran-
scription factor involved in the regulation of cell signal-
ing responses. It is a key regulator of cellular processes
involved in the immune response, differentiation, cell
proliferation, and apoptosis [1,2]. NF-B is secreted pre-
dominantly in cytoplasm in the form of an inactive
complex with IB inhibitor proteins. Binding to IB
(Inhibitor of kappa B) prevents NF-B:IBc o m p l e x
from translocating to the nucleus, thereby maintaining
NF-B in an inactive state. NF-B signalling is generally
considered to occur through NF-B activation being
inititated by stimuli like proinflammatory cytokine TNF
(tumor necrosis factor) alpha and bacterial lipopolysac-
charide (LPS). Signalling pathways lead to activation of
the beta subunit of the IKK (IB kinase) complex, which
then phosphorylates IB proteins leading to their degra-
dation and subsequent release of NF-B. The freed
NF-B dimers translocate to the nucleus where it binds
to the target genes. The constitutive activation of NF-B
contributes to multiple cellular outcomes and pathophy-
siological conditions such as rheumatoid arthritis,
asthma, inflammatory bowel disease [3], AIDS [4] and
cancer [5]. Thus there lies a huge therapeutic potential
beneath inhibition of NF-B signalling pathway for
reducing menace of these chronic ailments [6].
Degradation of IB is a tightly regulated event that is
initiated upon specific phosphorylation by activated IKK.
IKK is a multisubunit complex that contains two kinase
subunits, IKKa (IKK1) and IKKb (IKK2), and a regula-
tory subunit, NEMO (NF-B Essential Modulator) or
IKKc [7]. In the classical NF-B signalling pathway,
IKKb is both necessary and sufficient for phosphoryla-
tion of IBa on Ser 32 and Ser 36, and IBb on Ser 19
and Ser 23. Thus inhibition of NEMO/IKKb complex
assembly by employment of small molecule inhibitors
can offer a modest mode of inhibition of NF-Ba c t i v a -
tion while providing additional favors of oral administra-
tion and decreased immunogenicity.
Withania somnifera,a l s ok n o w na s“ashwagandha”,
“Queen of Ayurveda”, “Indian ginseng”,a n d“winter
cherry”, has been an important herb in the Ayurvedic
and indigenous medical systems for more than 3,000
years [8]. Its roots have been used as herb remedy to
treat a variety of ailments and to promote general well-
ness. It has received much attention in recent years due
to the presence of a large number of alkaloids and ster-
oidal lactones known as withanolides [9,10]. Many of
Ashwagandha’s pharmacological activities have been
attributed to two primary withanolides: withaferin A
(WA) and withanolide D. The principal withanolide in
the Indian variety of the plant is WA. This drug is
known to have anti-inflammatory [11], antitumor [12],
antibacterial [13], antioxidant [14], anticonvulsive [15],
and immunosuppressive properties [16]. It has the
potential to increase tumor sensitization to radiation
and chemotherapy while reducing some of the most
common side effects of these conventional therapies
[17]. Long-term effects of W. somnifera on adjuvant-
induced arthritis in rats have also been reported [18].
Most recently, these were shown to potentiate apoptosis
of tumor cells by suppression of NF-B activation
[19-21], protect against UV-induced skin cancer [22]
and enhance neurite regeneration and memory [23,24].
Thus, many studies have been reported depicting the
effect of WA on suppression of NF-B activation, but
the mechanism behind this effect is still eluding the
researchers. The study conducted here is an attempt to
e l u c i d a t eap o s s i b l em o d eo fa c t i o no fWithania somni-
fera’s major constituent WA on NF-B signalling path-
way using molecular docking studies.
Structural aspects of NEMO/IKKb association domain
The structural features of the receptor macromolecule
[PDB: 3BRV] have been described in detail elsewhere
[25] by the depositors of the crystal structure to the
Protein Data Bank. Briefly, the protein is a 4-helix bun-
dle of NEMO and IKKb domains each consisting of two
chains B, D and A, C respectively as shown in Figure 1.
NEMO density extends from residues 49 to 109 in
chain B and from 49 to 109 in chain D. The IKK pep-
tide density extends from residues 705 to 743 in chain
A and from residues 701-744 in chain C. N and C ter-
mini of NEMO chains B and D form dimerization
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Page 2 of 11patches on the ends where the two IKK peptides attach
themselves. The IKK peptides are almost helical except
for an unwound stretch ranging from 732 to 742. The
interactions between side chain tryptophans and main
chain amides cause constriction in the backbone result-
ing in this unwounding region. Each of the IKKb
peptide chain associate loosely with the corresponding
NEMO chains at their N-terminus but they are strin-
gently attached to the two NEMO chains at the C-ter-
minus. The authors have assigned three regions within
the IKKb peptide, designated as helical (705–731), linker
(732–736), and the NBD (NEMO Binding Domain)
(737–742). Residues 85–1 0 1o fd i m e r i cN E M Of o r ma
flat slit paving way to two broad and extensive IKK-
binding pockets; each pocket being occupied by the IKK
peptide linker and the NBD. The IKK peptide forms
intermolecular hydrogen-bond interactions (Ser85:Q730
and Glu89:S733) with NEMO in the NEMO’ss p e c i f i c i t y
pocket. Three large IKK side chains inside the NEMO
pocket which form consolidated intermolecular hydro-
phobic interactions (Leu93:F734, Phe92:T735, Met94:
F734, Phe97:W739, Ala100:W741, and Arg101:W741)
are responsible for formation of NEMO-IKKb complex.
Methods
Ligand and receptors
The crystal structure of the NEMO/IKKb association
domain [PDB: 3BRV] was obtained from the Protein
Data Bank (PDB) [26]. The crystal structure contained
many missing atoms which were supplemented by the
repairCommands module of AutoDock. Before docking,
the protein crystal structure was cleaned by removing the
water molecules. H-atoms were added to these target
proteins for correct ionization and tautomeric states of
amino acid residues. The modified structure so obtained
was used for all the flexible docking studies while only
NEMO chains were used for performing semi-flexible
dockings. The ligand molecule withaferin A [Pub-
Chem:265237] was retrieved from NCBI-PubChem Com-
pound database [27]. Figure 2 shows the basic skeleton of
withanolides along with the structure withaferin A. The
energy of the ligand molecule and receptors were mini-
mized in Steepest Descent and Conjugate Gradient meth-
ods using Accelrys Discovery Studio (Version 1.7,
Accelrys Software Inc.), the most comprehensive suite of
modeling and simulation solutions for drug discovery
available. Each of the minimization methods were carried
out with CHARMm force field.
Semi-flexible docking
AutoDock 4.0 suite was used as molecular-docking tool in
order to carry out the docking simulations [28]. Several
studies report the comparison of AutoDock with various
docking programs. AutoDock has been found to be able to
locate docking modes that are consistent with X-ray crys-
tal structures [29,30]. AutoDock helps to simulate interac-
tions between substrates or drug candidates as ligands and
their macromolecular receptors of known three dimen-
sional structures, allowing ligand flexibility described to a
full extent elsewhere [28]. In our docking simulations we
Figure 1 Ribbon structure of NEMO/IKKb complex. Chains B
(pink) and D (green) constitutes the NEMO domain while chains A
(cyan) and C (yellow) represent secondary structure of IKKb.
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association domain structure for performing semi-flexible
docking, with the ligand WA made flexible while keeping
the receptor macromolecule being rigid. Flexibility of the
ligand helps it explore six spatial degrees of freedom for
rotation and translation and an arbitrary number of tor-
sional degrees of freedom. A random perturbation to each
is applied at each time step, and the interaction energy
was evaluated for the new location and conformation [31].
Flexible docking
O n eo ft h en o v e lf e a t u r e so fA u t o D o c k4 . 0a l l o w ss i d e
chains in the protein as well as in the ligand to be flex-
ible. Thus flexibility of receptor molecule was also
exploited in docking studies by making use of AutoDock
flexres scripts. It is worth assumable that the incoming
ligand arriving at the binding sites of the two chains
would try to make its own associations with the residues
in order to minimize the energy of the system. To facili-
tate this notion, the key residues of NEMO and IKKb
chains which form H-bonds with corresponding residues
in the two chains as reported [25] were made flexible in
order to observe their mode of interactions with the
ligand and to account for the subsequent rearrange-
ments. The peptide bonds of the amino acids chosen to
be flexible were kept “inactive” or non-rotatable. The
Graphical User Interface program “AutoDock Tools”
was used to prepare, run, and analyze the docking simu-
lations. Protein was prepared for docking simulations by
assigning of Kollman united atom charges, solvation
parameters and polar hydrogens to the receptor PDB
file. Water molecules were removed from its PDB file to
make it a free receptor. Since ligands are not peptides,
Gasteiger charge was assigned and then nonpolar hydro-
gens were merged. AutoDock assigns the rigid roots to
the ligand automatically saving time as compared to
manual picking. Five bonds in the ligand were made
“active” or rotatable. Atomic solvation parameters were
assigned to the receptor using default parameters.
Grid design
Auto-Tors, an auxiliary program using Interactive
queries to define rotatable torsion angles, is used to
assign all rotatable dihedrals in the ligands and to
remove non-polar hydrogen atoms, uniting their partial
charges with their bonded carbon atoms. AutoGrid,
which calculates grids of interaction energy based on
the interaction of the ligand atom probes with receptor
target, is used to obtain the grid maps required prior to
docking. Each probe consists of an atom type present in
the ligand being docked. The pre-calculated grid maps
store the potential energy arising from the interaction
with the macromolecule. The user defined three dimen-
sional grid must surround the region of interest in the
macromolecule, and the ligand was limited to this
search space during docking. In the present study, the
location and dimensions of the grid box are chosen
such that it incorporates the amino acid stretch (85-
101) of NEMO domain involved in binding with the
IKKb chains for the formation of active IKK complex.
The energy scoring grid was prepared as a 60, 60, and
60 A° (x, y, and z) cube. The spacing between grid
points was 0.375 angstroms.
The genetic algorithm
The Lamarckian Genetic Algorithm (LGA) was chosen
to search for the best conformers. Using mathematical
concepts designed to simulate the conditions
Figure 2 Structures of withanolides. (A) Withaferin A falls under
the family of compounds known as withanolides which are a group
of naturally occurring C28- steroidal lactones built on an intact or
rearranged ergostane framework, in which C-22 and C- 26 are
appropriately oxidized to form a six-membered lactone ring. The
basic structure is designated as the withanolide skeleton defined as
a 22-hydroxyergostan-26-oic acid-26,22-lactone. (B) Structure of
withaferin A.
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able to search conformational space by “mutating” a
ligand in order to find its lowest energy conformation
in the “environment” of a fixed protein. Searches dri-
v e nb yt h i se n e r g yf u n n e l l i n gh a v eb e e ns h o w nt op r o -
vide a good indication as to the optimum protein-
ligand interactions and therefore conveying the struc-
ture most likely to be found in vivo[32]. The default
parameters for the Lamarckian genetic algorithm [28]
were used as the search protocol except for the maxi-
mum number of energy evaluations, which were chan-
ged to 2.5 million. During the docking process, a
maximum of 20 conformers was considered for each
compound. The population size was set to 150 and the
individuals were initialized randomly. Maximum num-
ber of generations were kept as 1000, maximum num-
ber of top individual that automatically survived set to
1, mutation rate of 0.02, crossover rate of 0.8. Step
sizes for translations, quaternions and torsions were
kept same as defaults. An efficient and accurate energy
assessment of the ligand conformations is as important
to the success of a docking simulation as the power of
the search algorithm. AutoDock uses a variation on
the AMBER’95 force field [33] with terms empirically
determined by linear regression analysis from a set of
protein-ligand complexes with known binding con-
stants [28,34]. Gibbs Free energy (ΔG) is calculated as
as u mo fs i xe n e r g yt e r m so fdispersion/repulsion,
hydrogen bonding, electrostatic interactions, deviation
from covalent geometry, internal ligand torsional con-
straints, and desolvation effects.
Selection and representation of docking modes
AutoDock reports the best docking solution (lowest
docked free energy) for each GA run and also per-
forms a cluster analysis in which the total number of
clusters and the rank of each docking mode (cluster
rank) are reported. Docking modes were selected on
the basis of two criteria: ligand’s proximity to the N-
terminal Glutamine and extent of its interactions with
the IKKa and IKKb interacting hydrophobic amino
acid side chains of NEMO. For a 10 GA run there
would be up to 10 total docking modes from which
the lowest energy-docking mode was chosen that met
the above two criteria. All the AutoDock docking runs
were performed in Intel Core 2 Duo P8400 CPU @
2 . 2 6G H zo fS o n yo r i g i n ,w i t h3G BD D RR A M .A u t o -
Dock 4.0 was compiled and run under Windows
VISTA operating system. The output from AutoDock
a n da l lm o d e l i n gs t u d i e sa sw e l la si m a g e sw e r er e n -
dered with PyMOL [35] and Accelerys ViewerLite 5.0.
PyMOL was used to calculate the distances of hydro-
gen bonds as measured between the hydrogen and its
assumed binding partner.
Confirmation of the docking results
The docking results obtained using AutoDock were also
confirmed using ParDOCK [36] , which is an all atom
energy based monte carlo docking protocol. Docking
using ParDOCK requires a reference complex (target
protein bound to a reference ligand) and a candidate
molecule along with specific mention of the centre of
mass of the cavity on which the ligand is to be docked.
MD simulations in water
The AMBER v.10 package [37]was used to prepare the
protein and the ligand files as well as for the Molecular
Dynamics (MD) simulations. The binding complex of
NEMO/IKKb/WA obtained using ParDOCK and the
free protein simulated in this study were neutralized by
adding appropriate number of sodium counter-ions and
was solvated in a octahedron box of TIP3P water with a
1 0Åd i s t a n c eb e t w e e nt h ep r o t e i ns u r f a c ea n dt h eb o x
boundary [38]. The partial atomic charges for the ligand
were obtained using “antechamber” [39] module of
Amber.
The energy minimization and MD simulations of
NEMO/IKKb and its complex with WA were carried
out with the aid of the SANDER module of the AMBER
10 program. First of all, the simulated binding complex
was effected with a 1000 step minimization using the
steepest descent algorithm followed by a 2000 step
minimization using conjugate gradient to remove bad
steric contacts. Topology and parameter files for the
protein were generated using “ff03” and for the drug
using “gaff” based on the atom types of the force field
model developed by Cornell et al [33]. Then the system
was equilibrated beginning with the protein atom
restrained simulations having 20 ps equilibration
dynamics of the solvent molecules at 300 K and a har-
monic potential with a 10 kcal/mol restraint force. Next
step involved the equilibration of the solute molecules
with a fixed configuration of the solvent molecules in
which the system was slowly heated from T = 10 to 300
K in three intervals of 20 ps each. The entire system
was then equilibrated at 300 K for 70 ps before a suffi-
ciently long MD simulation (for 2.6 ns) at room tem-
perature. The MD simulations were performed with a
periodic boundary condition in the NPT ensemble at
T=298.15 K with Berendsen temperature coupling [40]
and constant pressure P=1 atm with isotropic molecule-
based scaling . The SHAKE algorithm [41] was applied
to fix all covalent bonds containing hydrogen atoms.
We used a time step of 2 fs and a nonbond-interaction
cutoff radius of 10 A°. The Particle Mesh Ewald (PME)
method [42] was used to treat long-range electrostatic
interactions. The coordinates of the trajectory was
sampled every 1 ps for analysis of the energy stabiliza-
tion and RMSD values of the protein as well as that of
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processors SUN Microsystems clusters at Supercomput-
ing Facility (SCFBio) at IIT Delhi.
Results and discussion
Semi-flexible docking of WA into NEMO
One possible mode of action which is proposed here for
WA to act as a NF-B activation suppressor is by non-
formation/disruption of the complex between NEMO
and IKKb. In order to explore the possibility of non-for-
mation of the complex, we first carried out molecular
docking studies with only the NEMO chains of the pro-
tein crystal structure. Before docking to be carried out,
the structures of receptor macromolecules were mini-
mized in Steepest Descent and Conjugate Gradient
methods using Accelrys Discovery studio. Macromolecu-
lar receptors minimized using Conjugate Gradient have
comparatively lower potential energy values than those
obtained from Steepest Descent and are thus utilized
further for carrying out the docking studies. Figure 3A
shows the docked ligand WA to the selective NEMO
receptor. WA gets buried inside the pocket of NEMO as
depicted by mesh representation in Figure 3B. For this
particular configuration the binding energy of WA with
NEMO is -9.44 Kcal/mol (Table 1).
The binding of WA to NEMO is characterized by
H-bonding between a terminal hydroxyl group of the
ligand and the side chain carboxyl group of Glu 89
(Figure 4A). The residue Glu 89 has been reported as
one of the critical residues being involved in H-bond
formation with Ser 733 of IKKb resulting in complex
formation with NEMO [25]. The lengths of the two H-
bonds formed are 1.86 and 2.93 Å. The other end of
Figure 3 Docking representations of Withaferin A. (A) Ligand
docked into the NEMO receptor cavity (B) Docked Ligand inside the
pocket of NEMO receptor mesh.
Table 1 Energies obtained after docking of withaferin A
into NEMO
Property Quantity
Binding Energy -9.44 Kcal/mol
Intermolecular energy -9.68 Kcal/mol
Total internal energy -1.13 Kcal/mol
Figure 4 Interactions of docked withaferin A with NEMO
receptor. (A) H-Bond interactions of the docked ligand with NEMO
residues. (B) Docked withaferin A forming vdw interactions with the
hydrophobic residues of NEMO.
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group of Glu 99 with a bond distance of 2.35 Å. It has
also been reported that the residues Phe 92, Leu 93,
Met 94, Phe 97, Ala 100 and Arg 101 of NEMO are
responsible for intermolecular hydrophobic interactions.
In the present docked structure, WA is forming van der
Waals interactions with Phe 92, Leu 93, Phe 97 and Ala
100 of NEMO (Figure 4B). These non-covalent interac-
tions help stabilize the binding of the ligand with the
macromolecule by lowering the energy. Strong interac-
tions formed by WA with these particular residues
would result in building steric as well as thermodynamic
barriers to the incoming IKKb subunits, thus providing
hindrance for binding to NEMO at these particular resi-
dues. This obstruction would pave way to unlikely com-
plex formation capability of NEMO to IKKb yielding in
either the formation of a deformed complex or at
extreme no complex formation at all. Moreover the
deformed complex would be thermodynamically much
less stable as compared to the native complex owing to
the non-availability of WA occupied hydrophobic inter-
action forming residues of NEMO. In both cases the
NEMO/IKKb complex would not get assembled to its
catalytically active form. The absence of active IKK mul-
tisubunit complex would prevent degradation of IB
proteins, as the IB proteins would not get phosphory-
lated by IKK. This would ultimately lead to non-release
of NF-B and its further translocation to the nucleus
thus arresting its nefarious acts.
Flexible docking of WA into active NEMO/IKKb complex
Docking of WA performed on the catalytically active
NEMO/IKKb complex also provided interesting results.
The binding of WA to NEMO provides significant evi-
dence in support of the proposed mechanism of NF-B
activation suppression by inhibition or disruption of
active NEMO/IKKb complex formation. Four clusters
were obtained for Genetic Algorithm run for generation
of twenty models. Large negative binding energies were
obtained for all the clusters as evident from Table 2.
The lowest binding energy was more than twice as
lower as that of the energy obtained from binding of
WA to the segregated NEMO receptor. As shown in
Figure 5 for Cluster 1, the hydroxyl group of WA
disrupts SER733:GLU89 H-bond present in the active
complex by itself hydrogen bonding with SER733 hydro-
xyl group. The same hydroxyl group of the ligand is also
involved in H-bonding with THR735, which is one of
the critical residues in complex formation. The other
terminal hydroxyl group of WA is also involved in form-
ing H-bonds with SER740 and ASP738 of chain A.
NEMO and IKKb chains of active NEMO/IKKb com-
plex are held together by strong intermolecular hydro-
phobic interactions between LEU93:PHE734, THR735:
PHE92, PHE734:MET94, TRP739:PHE97, TRP741:
ALA100, TRP741:ARG101. But withefrin A disrupts
majority of these hydrophobic interactions by placing
itself in between the binding chains, As depicted in
Figure 6 for Cluster 1, WA itself starts forming strong
intermolecular interactions with these critical residues.
T h ee n e r g yv a l u e sf o rt h ed i f f e r e n tc l u s t e r ss h o w ni n
Table 2 can be explained on the basis of the representa-
tive cluster structures, which are the ones having lowest
energy in the respective cluster (Figure 7). All the
hydrogen bonds being formed in cluster 1 (Ser 733,
Thr 735, Asp 738 and Ser 740) were lost in cluster 2
(Figure 7A) which explains the increase in energy for
this cluster as compared to cluster 1. But the amount of
energy lowered is not that much significant owing to
the presence of strong van der Waals interactions with
Phe 92, Leu 93 and Phe 97 of chain B. In cluster 3
(Figure 7B), though there is formation of few hydrogen
bonds with residues of chain A, the van der Waals inter-
actions are also markedly reduced resulting in further
decrease in energy. In cluster 4 (Figure 7C), due to the
absence of any hydrogen bond formation in addition to
very weak van der Waals interactions, the energy is
recorded as minimum of all the four clusters.
The results obtained (Figure 5 &6) from docking
of WA into the active complex, with a majority of
H-bond and hydrophobic interaction forming residues
kept flexible, clearly show that WA blocks the inter-
molecular hydrophobic interactions between NEMO
and IKKb at the residues which are significantly
involved in formation of the active complex. The large
value of binding energy for Cluster 1(-19.33 Kcal/mol)
involved in binding of WA to the complex consolidates
the thermodynamic stability of the binding. These











1 8 -19.33 -19.33 to -17.24
NEMO/IKKb complex 4 (20) 2 8 -19.12 -19.12 to -16.53
3 3 -18.6 -18.6 to -16.99
4 1 -18.33 -18.33
a Number of GA runs are shown in parentheses
b Clustering is done with RMS tolerance of 5.0 Å
Grover et al. BMC Genomics 2010, 11(Suppl 4):S25
http://www.biomedcentral.com/1471-2164/11/S4/S25
Page 7 of 11results substantiate the hypothesis that WA possess the
potential to disarray the active complex by disrupting
the stability of attachment of NEMO and IKKb chains,
being accounted by hydrophobic and H-bond
interactions.
Figure 5 H-bonding interactions present in the docked
complex of withaferin A with active NEMO/IKKb complex using
flexible docking. Polar hydroxyl terminal group of withaferin A
captivates hydroxyl group of SER 733 to form H-bond with itself,
thus disrupting the earlier present SER 733 - GLU 89 H-bond.
Figure 6 Hydrophobic interactions present in the complex
obtained from docking of withaferin A into active NEMO/IKKb
complex using flexible docking
Figure 7 Interactions of docked withaferin A with NEMO/IKKb
in the representative structures of different clusters using
flexible docking. (A) Cluster 2 – no hydrogen bond formation
takes place (B) Cluster 3 – formation of few hydrogen bonds in
addition to weak van der Waals interactions (C) Cluster 4 – no
hydrogen bond formation in addition to weak van der Waals
interactions.
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The NEMO/IKKb/WA protein-drug binding complex
with the binding energy of -9.33 kcal/mol obtained
using ParDOCK (Figure 8) was used for carrying out
MD simulations. After the MD simulation, we calcu-
lated RMSDs between Ca of NEMO/IKKb complex
trajectories recorded every 1 ps and Ca of their X-ray
crystal structure. The RMSDs for the trajectories of
the NEMO/IKKb complexed with WA were also calcu-
lated using its initial model as a reference structure.
The results in Figure 9A show that the RMSD of the
complex has achieved a stationary phase during the
later stage of the simulation and is always less than 3
Åf o rt h ee n t i r es i m u l a t i o nl ength suggesting the stabi-
lity of the complex, while the RMSDs of the protein
from its initial X-ray PDB structure kept increasing. It
was also found that the energy of the complex (blue) is
always lower than that of the protein (red) alone
throughout the length of the simulation (Figure 9B).
This rule out the possibility of the complex getting
activated in the presence of WA. It was also observed
that the water molecules act as intermediate bridges
thus playing a vital role in facilitating the binding of
ligand to the protein (Figure 10). The MD simulations
were also carried out for WA complex with NEMO. It
was observed that RMSD for this complex kept
increasing with marked fluctuations (Figure 11). Thus
the WA complex with NEMO alone seems to be quite
unstable. The simulation length used in the entire
study were long enough to allow rearrangement of side
chains of the native as well as the drug complexed
protein to find their most stable binding mode. In con-
clusion, the present MD simulations made clear the
dynamic structural stability of NEMO/IKKb in com-
plex with the drug WA, together with the inhibitory
mechanism. These results would be valuable for
Figure 8 Docking representation of the drug WA inside the
cavity of NEMO/IKKb obtained using ParDOCK.
Figure 9 (A) Plot of root mean square deviation (RMSD) of Ca
of NEMO/IKKb (protein) and NEMO/IKKb/WA (complex). RMSDs
were calculated using the initial structures as templates. For protein
(red) the reference is the PDB structure and for complex (blue) the
reference is the initial model. The trajectories were captured every 1
ps until the simulation time reached 2600 ps. (B) Plot of total
energy of NEMO/IKKb and NEMO/IKKb/WA (complex) The
energy trajectories of both the protein (red) and the complex (blue)
are stable over the entire length of simulation time.
Figure 10 A simulated snapshot of WA/NEMO/IKKb complex
showing water molecules coordinating the ligand and the
protein. The water molecules act as intermediate bridges
facilitating the binding of WA to NEMO/IKKb.
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Page 9 of 11further designing non-covalent type inhibitors with
high specificity and potent activity.
Conclusions
NF-B is one of the most attractive topics in current
biological, biochemical, and pharmacological research,
and in the recent years the number of studies focusing
on its inhibition/regulation has increased manifolds.
Small ligands (both natural and synthetic) are gaining
particular attention in this context. Our computational
analysis, provided a rationalization of the ability of natu-
rally occurring WA to alter the NF-B signalling path-
way. The large value of binding energy involved in
binding of WA to the active NEMO/IKK complex con-
solidates the thermodynamic stability of the binding.
Our docking results obtained substantiate the hypothesis
that WA has the potential to inhibit the formation of
active NEMO/IKK complex by either resulting in non-
formation of the complex or by disrupting the stability
of attachment of NEMO to IKKb chains. Conclusively
our results strongly suggest that withaferin A is a potent
anticancer agent as ascertained by its potent NF-B
modulating capability.
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